FIELD: medicine.
SUBSTANCE: group of inventions relates to a stable peptide composition comprising: a self-assembling peptide; buffer agent containing at least one substance selected from a group, consisting of histidine, thiamine nitrate, pyridine, bis-tris, ethylenediamine and/or N-methylmorpholine; and water, wherein stable peptide composition has pH from 4.5 to 6.6; wherein the total charge of the amino acid residues contained in the self-assembling peptide is between more than 0 and +3 or less in the stable peptide composition; wherein the C-terminal of the self-assembling peptide includes an amide group; wherein the amino acid at the C-terminal of the self-assembling peptide contains a basic amino acid; wherein the self-assembling peptide is formed from the following amino acid sequence: a1b1c1b2a2b3db4a3b5c2b6a4, where each residue a1–a4 is a basic amino acid residue, each residue b1–b6 is an uncharged polar amino acid residue and/or a hydrophobic amino acid residue, provided that at least five of them are a hydrophobic amino acid residue, each residue c1–c2 is an acidic amino acid residue and d is a hydrophobic amino acid residue; wherein the self-assembling peptide contains a peptide formed by the amino acid sequence: n-RLDLRLALRLDLR-c (SEQ ID NO:1), n-RLDLRLSLRLDLR-c (SEQ ID NO:2), n-RLALRLDLRLDLR-c (SEQ ID NO:3), n-KRLDLNLRLDLRK-c (SEQ ID NO:4), and also relates to a method of producing a stable peptide composition.
EFFECT: group of inventions provides a stable and transparent peptide composition.
4 cl, 4 tbl, 14 ex
Title | Year | Author | Number |
---|---|---|---|
INSULINOTROPIC PEPTIDE DERIVATIVE WITH MODIFIED N-TERMINAL CHARGE | 2014 |
|
RU2673179C2 |
ANTIBIOTIC PEPTIDES | 2008 |
|
RU2472805C2 |
INDIVIDUAL DENTAL CARE PRODUCT FOR PREVENTING DEMINERALISATION | 2020 |
|
RU2834399C1 |
CONTROLLED RELEASE THERAPEUTIC AGENTS CONTAINING PEPTIDES | 2009 |
|
RU2543327C2 |
GLUCAGON ANALOGUES, HAVING HIGH SOLUBILITY IN PHYSIOLOGICAL pH BUFFERS | 2008 |
|
RU2477286C2 |
PROCESS FOR PREPARATION OF GLYCOPEPTIDE HAVING SIALYLATED SUGAR CHAIN, AND METHOD FOR PRODUCING SIALYL GLYCOASPARAGINE | 2012 |
|
RU2586524C2 |
HEMOSTATIC COMPOSITIONS | 2016 |
|
RU2744694C2 |
DUAL GLP1/GIP OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | 2013 |
|
RU2652783C2 |
METHOD OF PRODUCING PEPTIDE | 2008 |
|
RU2478105C2 |
MOTILIN-LIKE PEPTIDE COMPOUND HAVING IMPARTED TRANSMUCOSAL ABSORBING ABILITY | 2010 |
|
RU2540012C2 |
Authors
Dates
2021-01-12—Published
2015-12-10—Filed